Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis

ABSTRACT

Objectives: To assess the risk of adverse events (AEs) associated with brentuximab vedotin in lymphoma patients.

Methods: Articles were retrieved from PubMed, Cochrane, and Clinicaltrials Databases to identify randomized controlled trials (RCTs) comparing brentuximab vedotin with non-brentuximab vedotin in lymphoma patients.

Results: A total of 2225 patients from 4 RCTs were included. Compared with the non-brentuximab vedotin group, the brentuximab vedotin group significantly increased the risk of all-grade AEs (RR 1.05, 95% CI: 1.00–1.10), and high-grade AEs (risk ratio [RR] 1.27, 95% confidence intervals [CI]: 1.01–1.58). The brentuximab vedotin group significantly increased the risk of all-grade peripheral sensory neuropathy (RR 2.29, 95% CI: 1.23–4.26), pyrexia (RR 1.23, 95% CI: 1.05–1.44), nausea (RR 1.51, 95% CI: 1.05–2.18), vomiting (RR 1.54, 95% CI: 1.08–2.19), diarrhea (RR 1.69, 95% CI: 1.44–1.98), and alopecia (RR 1.18, 95% CI: 1.00–1.39), respectively. The brentuximab vedotin group significantly increased the risk of high-grade sensory neuropathy (RR 4.79, 95% CI: 1.46–15.75), neutropenia (RR 1.48, 95% CI: 1.01–2.18), nausea (RR 2.65, 95% CI: 1.37–5.12), vomiting (RR 2.2, 95% CI: 1.17–4.12), and diarrhea (RR 1.85, 95% CI: 1.21–2.85).

Conclusion: Brentuximab vedotin increased the risk of certain AEs in lymphoma patients.

KEYWORDS:

• Brentuximab vedotin
• adverse event
• lymphoma patients
• meta-analysis

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

A reviewer on this manuscript has disclosed that they were an investigator on the phase III randomized Aethera trial for Hodgkin lymphoma. A reviewer on this manuscript has disclosed that they have served on an advisory board for, and received consultancy fees from, Takeda. All other peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.

Additional information

Funding

This paper was funded by grants from the Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology (Grant[2013]163) and the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes (Grant KLB09001).